BLA 761107 · Novimmune S.A.
Gamifant
Emapalumab-Lzsg · Injection · Interferon gamma Blocker
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Mar 17, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Nov 20, 2018
Approved uses
2
Original approval plus efficacy supplements
Registered trials
29
8 Phase 3, 11 recruiting
FAERS reports
237
209 serious, 106 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 26, 2026.
GAMIFANT is indicated for the treatment of: adult and pediatric patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. adult and pediatric patients with HLH/macrophage activation syndrome (MAS) in known or suspected Still’s disease, including systemic Juvenile Idiopathic Arthritis (sJIA), with an inadequate response or intolerance to glucocorticoids, or with recurrent MAS. GAMIFANT is an interferon gamma (IFNγ) neutralizing antibody indicated for the treatment of: adult and pediatric patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. ( 1 ) adult and pediatric patients with HLH/macrophage activation syndrome (MAS) in known or suspected Still’s disease, including systemic Juvenile Idiopathic Arthritis (sJIA), with an inadequate response or intolerance to glucocorticoids, or with recurrent MAS. ( 1 )
Mechanism: Emapalumab-lzsg is a monoclonal antibody that binds to and neutralizes interferon gamma (IFNγ). Nonclinical data suggest that IFNγ plays a pivotal role in the pathogenesis of HLH by being hypersecreted.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 27, 2025 Supplement 18 · Efficacy · priority review OrphanLetterLabel
- Nov 20, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLetterLabelReview
3 products under this application
- GAMIFANT · EMAPALUMAB-LZSG 100MG/20ML · INJECTABLE, INJECTION · Prescription
- GAMIFANT · EMAPALUMAB-LZSG 10MG/2ML · INJECTABLE, INJECTION · Prescription
- GAMIFANT · EMAPALUMAB-LZSG 50MG/10ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Emapalumab" as an intervention, any sponsor and status, largest first.
Hellenic Institute for the Study of SepsisAcademic, hospital or other
NCT06694701 · 75 participants · Start Mar 14, 2025 · Primary completion Mar 13, 2026
Drug: Emapalumab-Izsg; Emapalumab-Izsg and 1 more · For: Sepsis
Sites: Elefsina, Greece; Kifissia, Greece; Heraklion, Greece · 24 sites in all
- Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANSNot yet recruiting
NYU Langone HealthAcademic, hospital or other
NCT07567014 · 60 participants (planned) · Start May 11, 2026 · Primary completion May 31, 2028
Drug: Emapalumab · For: Multiple Myeloma; Large B-cell Lymphoma (LBCL)
Sites: Brooklyn, New York; Manhattan, New York; Mineola, New York
- A Study for Long-term Follow-up of Hemophagocytic Lymphohistiocytosis (HLH) Participants Who Received Treatment With Emapalumab (NI-0501), an Anti-interferon Gamma Monoclonal AntibodyPivotal-lookingCompleted
Swedish Orphan BiovitrumIndustry
NCT02069899 · 58 participants · Start Aug 4, 2014 · Primary completion May 18, 2021
Drug: Emapalumab · For: Hemophagocytic Lymphohistiocytosis
Sites: Grand Rapids, Michigan; Chapel Hill, North Carolina; Cincinnati, Ohio · 16 sites in all
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT05463133 · 50 participants (planned) · Start Jul 8, 2022 · Primary completion Dec 31, 2032
Drug: Sirolimus; Cyclophosphamide and 6 more · For: Chronic Granulomatous Disease
Sites: Bethesda, Maryland
- Study to Investigate Safety, Efficacy of an Anti-IFNγ mAb in Children With Primary Haemophagocytic LymphohistiocytosisPivotal-lookingCompleted
Swedish Orphan BiovitrumIndustry
NCT01818492 · 45 participants · Start Jul 2013 · Primary completion Jan 2019
Drug: NI-0501 · For: Primary Haemophagocytic Lymphohistiocytosis
Sites: Aurora, Colorado; Wilmington, Delaware; Atlanta, Georgia · 20 sites in all
- Targeting Interferon Gamma With Emapalumab to Lung Transplant Recipients With Interferon Gamma-high Acute Lung Allograft DysfunctionNot yet recruiting
University of California, San FranciscoAcademic, hospital or other
NCT07538336 · 40 participants (planned) · Start Nov 2, 2026 · Primary completion Nov 1, 2028
Drug: Emapalumab; Placebo · For: Lung Transplant
Sites: Los Angeles, California; San Francisco, California
The First Affiliated Hospital of Soochow UniversityAcademic, hospital or other
NCT07270835 · 40 participants (planned) · Start Nov 1, 2025 · Primary completion Apr 2027
Drug: Rituximab; Zanubrutinib · For: Hemophagocytic Lymphohistiocytosis; B Cell Lymphoma
Sites: Suzhou, China
Joseph OvedAcademic, hospital or other
NCT05787574 · 39 participants (planned) · Start Mar 15, 2023 · Primary completion Mar 2027
Drug: Emapalumab; Fludarabine and Dexamethasone · For: Primary Immune Regulatory Disorder; Autoimmune Lymphoproliferative; Immune System Diseases
Sites: San Francisco, California; Atlanta, Georgia; Basking Ridge, New Jersey · 13 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use94
- haemophagocytic lymphohistiocytosis72
- condition aggravated60
- drug ineffective32
- death29
- septic shock21
- epstein-barr virus infection14
- multiple organ dysfunction syndrome14
- adenovirus infection13
- hypertension13
- pyrexia13
- serum ferritin increased12
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2019 | 17 |
| 2020 | 15 |
| 2021 | 12 |
| 2022 | 18 |
| 2023 | 18 |
| 2024 | 31 |
| 2025 | 62 |
| 2026 | 64 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Gamifant (Emapalumab-Lzsg) · HCPCS J9210
2024 spending
$7.0M
Beneficiaries
n/a
59 claims
Per beneficiary
n/a
2024 ASP limit $371.31 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $409,090 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $7,028,970 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis.
Locatelli F, Jordan MB, Allen C, et al. · N Engl J Med 2020 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Efficacy and safety of therapies for Still's disease and macrophage activation syndrome (MAS): a systematic review informing the EULAR/PReS guidelines for the management of Still's disease.
Bindoli S, De Matteis A, Mitrovic S, et al. · Ann Rheum Dis 2024 · Systematic Review
- Current treatment in macrophage activation syndrome worldwide: a systematic literature review to inform the METAPHOR project.
Baldo F, Erkens RGA, Mizuta M, et al. · Rheumatology (Oxford) 2025 · Systematic Review, Research Support, Non-U.S. Gov't
- Emapalumab in primary haemophagocytic lymphohistiocytosis and the pathogenic role of interferon gamma: A pharmacometric model-based approach.
Jacqmin P, Laveille C, Snoeck E, et al. · Br J Clin Pharmacol 2022 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Real-world use of emapalumab in hemophagocytic lymphohistiocytosis: a scoping review of published evidence.
Al-Mashdali AF, Mohamed F, Osman M, et al. · Front Pharmacol 2026 · Systematic Review
Sponsor: Novimmune S.A.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.